|
1
|
Ralapanawa U and Sivakanesan R:
Epidemiology and the magnitude of coronary artery disease and acute
coronary syndrome: A narrative review. J Epidemiol Glob Health.
11:169–177. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Poudel I, Tejpal C, Rashid H and Jahan N:
Major adverse cardiovascular events: An inevitable outcome of
ST-elevation myocardial infarction? A Literature Review. Cureus.
11(e5280)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vogel B, Mehta SR and Mehran R:
Reperfusion strategies in acute myocardial infarction and
multivessel disease. Nat Rev Cardiol. 14:665–678. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ottani F, Limbruno U, Latini R, Misuraca L
and Galvani M: Reperfusion in STEMI patients: Still a role for
cardioprotection? Minerva Cardioangiol. 66:452–463. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Muller O, Trana C and Eeckhout E:
Myocardial no-reflow treatment. Curr Vasc Pharmacol. 11:278–275.
2013.PubMed/NCBI
|
|
6
|
Soeda T, Higuma T, Abe N, Yamada M,
Yokoyama H, Shibutani S, Ong DS, Vergallo R, Minami Y, Lee H, et
al: Morphological predictors for no Reflow phenomenon after primary
percutaneous coronary intervention in patients with ST-segment
elevation myocardial infarction caused by plaque rupture. Eur Heart
J Cardiovasc Imaging. 18:103–110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Movahed MR and Butman SM: The pathogenesis
and treatment of no-reflow occurring during percutaneous coronary
intervention. Cardiovasc Revasc Med. 9(443)2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gurewich V: Fibrinolysis: A misunderstood
natural defense whose therapeutic potential is unknown. Cardiovasc
Drugs Ther. 33:749–753. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liu Y, Yang Y, Li Y and Peng X: Comparison
of efficacy and safety of recombinant human prourokinase and
alteplase in the treatment of STEMI and analysis of influencing
factors of efficacy. Evid Based Complement Alternat Med.
2021(6702965)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen T, Wang Q, Liu G, Jin Q, Liu C, Gao
L, Chen Y and Guo J: Safety and efficacy of intracoronary
thrombolytic therapy via a new infusion catheter in patients with
ST-segment elevation myocardial infarction with large thrombus
burden: A pilot study. Coron Artery Dis. 32:205–210.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yao Z, Li W, Cheng L, Cao M, Pang Z and Li
Y: Comparison of the effect of recombinant human pro-urokinase and
tirofiban on myocardial blood flow perfusion in ST elevation
myocardial infarction patients receiving primary percutaneous
coronary intervention: A one-center retrospective observational
study. Medicine (Baltimore). 98(e16143)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gao J, Wang WJ, Liu YH and Luo DL:
Efficacy analysis of half-dose recombinant human prourokinase
thromboiysis compined with early PCI in 48 patients with
ST-segment-elevation myocardial infarction (STEMI). Asian J Surg:
Oct 6, 2022 (Epub ahead of print).
|
|
13
|
Beitland S, Sandven I, Kjærvik LK, Sandset
PM, Sunde K and Eken T: Thromboprophylaxis with low molecular
weight heparin versus unfractionated heparin in intensive care
patients: A systematic review with meta-analysis and trial
sequential analysis. Intensive Care Med. 41:1209–1219.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fan G, Zhang YW, Lin L, Chen M, Wei J and
Diao J: Optimal reperfusion strategy in patients with acute STEMI
and multivessel disease-an updated meta-analysis. Herz. 45:272–279.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wu Y, Fu X, Feng Q, Gu X, Hao G, Fan W and
Jiang Y: Efficacy and safety of intracoronary prourokinase during
percutaneous coronary intervention in treating ST-segment elevation
myocardial infarction patients: A randomized, controlled study. BMC
Cardiovasc Disord. 20(308)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jiang W, Xiong X, Du X, Ma H, Li W and
Cheng F: Safety and efficacy study of prourokinase injection during
primary percutaneous coronary intervention in acute ST-segment
elevation myocardial infarction. Coron Artery Dis. 32:25–30.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fu Y, Gu XS, Hao GZ, Jiang YF, Fan WZ, Fan
YM, Wei QM, Fu XH and Li YJ: Comparison of myocardial
microcirculatory perfusion after catheter-administered
intracoronary thrombolysis with anisodamine versus standard
thrombus aspiration in patients with ST-elevation myocardial
infarction. Catheter Cardiovasc Interv. 93:839–845. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang D, Qian J, Liu Z, Xu Y, Zhao X, Qiao
Z, Fang W, Jiang L, Hu W, Shen C, et al: Effects of Intracoronary
Pro-urokinase or tirofiban on coronary flow during primary
percutaneous coronary intervention for acute myocardial infarction:
A Multi-center, placebo-controlled, single-blind, randomized
clinical trial. Front Cardiovasc Med. 8(710994)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Geng W, Zhang Q, Liu J, Tian X, Zhen L,
Song D, Yang Y, Meng H, Wang Y and Chen J: A randomized study of
prourokinase during primary percutaneous coronary intervention in
acute ST-segment elevation myocardial infarction. J Interv Cardiol.
31:136–143. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xiao Y, Fu X, Wang Y, Fan Y, Wu Y, Wang W
and Zhang Q: Effects of different strategies on high thrombus
burden in patients with ST-segment elevation myocardial infarction
undergoing primary percutaneous coronary catheterization. Coron
Artery Dis. 30:555–563. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang X, Liu H, Wu H, Xiao Y, Bai S, Li X,
Li X, Zhang L, Chen T, Li H, et al: Safety and efficacy of
intracoronary prourokinase administration in patients with high
thrombus burden. Coron Artery Dis. 31:493–499. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lin D, Fu G, Chun HZ, Lixia M and Luohui
and Zhaofei W: Effect of low-dose recombinant human prourokinase
and tirofiban on myocardial perfusion in STEMI patients with
primary PCI. J Clin Cardiol (China). 37:215–219. 2021.(In
Chinese).
|
|
23
|
Yong W, Gao J, Hu J, Wang Y, Qing H and
Pei L: Improvement of combined application of sodium nitroprusside
and recombinant human prourokinase in coronary artery on no-reflow
in elderly patients with acute STEMI during emergency PCI.
Evolution Analysis Drug-Use Hosp China. 21:19–22. 2021.(In
Chinese).
|
|
24
|
Zhao X, Lu S, Jie C, Yang X and Huizhe W:
The evaluation of recombinant human prourokinase versus alteplase
in the treatment of acute STEMI. Med Sci J Central South China.
49:72–77. 2021.(In Chinese).
|
|
25
|
Han F, Haijun Z, Zhongming W, Cuiting Q,
Hui Z, Hui J, Jing L, Qingqing Z and Yanxia Z: Effect of
recombinant human prourokinase combined with sodium nitroprusside
and tirofiban by intracoronary injection on the efficacy of PCI in
STEMI patients with high thrombus load. Chin J Crit Care Med.
41:1028–1034. 2021.(In Chinese).
|
|
26
|
Han YL, Liu JN, Jing QM, Ma YY, Jiang TM,
Pu K, Zhao RP, Zhao X, Liu HW, Xu K, et al: The efficacy and safety
of pharmacoinvasive therapy with prourokinase for acute ST-segment
elevation myocardial infarction patients with expected long
percutaneous coronary intervention-related delay. Cardiovasc Ther.
31:285–290. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhao X, Shuangdong L, Jie C, Yang X and
Huizhe W: Preventive effect of recombinant human prourokinase on no
reflow phenomenon in patients with STEMI after PCI. J Prac
Cardiovas Dis. 29:105–109. 2021.(In Chinese).
|
|
28
|
Keeley EC, Boura JA and Grines CL: Primary
angioplasty versus intravenous thrombolytic therapy for acute
myocardial infarction: A quantitative review of 23 randomised
trials. Lancet. 361:13–20. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Morishima I, Sone T, Okumura K, Tsuboi H,
Kondo J, Mukawa H, Matsui H, Toki Y, Ito T and Hayakawa T:
Angiographic no-reflow phenomenon as a predictor of adverse
long-term outcome in patients treated with percutaneous
transluminal coronary angioplasty for first acute myocardial
infarction. J Am Coll Cardiol. 36:1202–1209. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ito H, Okamura A, Iwakura K, Masuyama T,
Hori M, Takiuchi S, Negoro S, Nakatsuchi Y, Taniyama Y, Higashino
Y, et al: Myocardial perfusion patterns related to thrombolysis in
myocardial infarction perfusion grades after coronary angioplasty
in patients with acute anterior wall myocardial infarction.
Circulation. 93:1993–1999. 1996.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dong-Bao L, Qi H, Zhi L, Shan W and
Wei-Ying J: Predictors and long-term prognosis of angiographic
slow/no-reflow phenomenon during emergency percutaneous coronary
intervention for ST-elevated acute myocardial infarction. Clin
Cardiol. 33:E7–E12. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kumar R, Khan KA, Shah JA, Ammar A, Kumar
D, Khowaja S, Sial JA, Kazmi S, Murtaza M and Karim M:
Quantification of thrombus burden as an independent predictor of
intra-procedural No-reflow in patients with St-segment elevation
myocardial infarction undergoing primary percutaneous coronary
revascularization. J Ayub Med Coll Abbottabad. 34:288–294.
2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Scarpone M, Cenko E and Manfrini O:
Coronary No-reflow phenomenon in clinical practice. Curr Pharm Des.
24:2927–2933. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Elgendy AY, Elgendy IY, Mahmoud AN and
Bavry AA: Long-term outcomes with aspiration thrombectomy for
patients undergoing primary percutaneous coronary intervention: A
meta-analysis of randomized trials. Clin Cardiol. 40:534–541.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang Z, Li W, Wu W, Xie Q, Li J, Zhang W
and Zhang Y: Myocardial reperfusion with tirofiban injection via
aspiration catheter: Efficacy and safety in STEMI patients with
large thrombus burden. Herz. 45:280–287. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang L, Qi X and Jia X: Effect of
different methods of administration of diltiazem on clinical
efficacy in patients with acute ST-segment elevation myocardial
infarction. Med Sci Monit. 24:6544–6550. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhao L, Zhao Z, Chen X, Li J, Liu J and Li
G: Group of Prourokinase Phase IV Clinical Trials Investigators.
Safety and efficacy of prourokinase injection in patients with
ST-elevation myocardial infarction: Phase IV clinical trials of the
prourokinase phase study. Heart Vessels. 33:507–512.
2018.PubMed/NCBI View Article : Google Scholar
|
